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patients have been exposed to cannabidiol in 
placebo-controlled trials, and the sample size for 
the analysis of effect modification by clobazam 
(among other factors) becomes larger, then it may 
be possible to better define the potential for clo-
bazam use to modify the effect of cannabidiol.
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Subclinical Hypothyroidism or Hypothyroxinemia in Pregnancy
To the Editor: The article by Casey et al. (March 2 
issue)1 and the accompanying editorial by Cooper 
and Pearce2 focus on the consequences of mater-
nal subclinical hypothyroidism for the neurocog-
nitive development of the offspring, which was 
unaffected by the normalization of thyrotropin 
levels. We suggest that mothers with subclinical 
hypothyroidism be treated, independently of the 
inability of a trial to show negative repercussions 
in offspring with the withholding of levothyroxine 
therapy.
Increased morbidity, among persons with 
hypothyroidism as well as among those with 
hyperthyroidism, may lead to excess mortality.3 
In a 7-year follow-up of more than 200,000 per-
sons, as compared with persons with normal 
thyrotropin levels, the risk of death increased by 
a factor of 1.09 for each 6 months that a person 
had a low (<0.30 mU per liter) thyrotropin level 
(P<0.001) and the risk increased by a factor of 
1.03 for each 6 months that a patient had an 
elevated (>4.00 mU per liter) thyrotropin level 
(P<0.001).4 Since the thyrotropin level is tightly 
genetically regulated,5 the exact level at which 
this risk increases in the individual patient is un-
known. Therefore, with regard to the trial con-
ducted by Casey et al., the decision to not treat 
mothers who have subclinical hypothyroidism, 
as well as the clinical tolerance of subclinical 
hyperthyroidism (thyrotropin level <0.30 mU per 
liter) in many of those treated with levothyroxine, 
may well cause harm, at least in the long term.
Laszlo Hegedüs, M.D., D.M.Sc. 
Thomas H. Brix, M.D., Ph.D.
University of Southern Denmark 
Odense, Denmark 
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To the Editor: Among women in the cohort 
with subclinical hypothyroidism in the trial re-
ported by Casey et al., randomization called for 
the exclusion of women who were classified as 
having overt hypothyroidism. Instead, obstetrical 
providers were notified of test results. The au-
thors call attention to the difference between 
their findings in women with subclinical hypo-
thyroidism and the results of our case–control 
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study in 1999 that focused on overt hypothyroid-
ism (thyrotropin level generally >10 mU per liter).1 
Among the offspring of women with overt hypo-
thyroidism, the average IQ was 7 points lower 
than among the offspring of control women.1 An 
estimated 3 to 5 pregnant women per 1000 have 
overt hypothyroidism.2 Under the assumption that 
ethical considerations in the present trial pre-
cluded the randomization of women with overt 
hypothyroidism, the dilemma posed is whether 
the IQ difference observed in 1999 can be con-
firmed in the absence of randomization. Mean-
while, we believe that available data in women 
with overt hypothyroidism provide support for 
screening in pregnancy.
James E. Haddow, M.D. 
Glenn E. Palomaki, Ph.D.
Women and Infants Hospital 
Providence, RI 
jhaddow@ ipmms . org
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The authors reply: Our primary objective was 
to determine whether routine screening and treat-
ment of otherwise healthy pregnant women for 
subclinical thyroid hypofunction would increase 
offspring IQ. Hegedüs and Brix suggest death as 
a potential harm in women with untreated sub-
clinical hypothyroidism during pregnancy. How-
ever, as highlighted in the references included in 
their letter, the risk of death that is associated 
with hypothyroidism is significantly confounded 
by other coexisting conditions, genetic predis-
position, and age at diagnosis. An increased risk 
of death was identified only among persons with 
overt hypothyroidism that was diagnosed after 
the age of 60 years. Excess mortality was also not 
identified among Danish persons with subclini-
cal hypothyroidism. Finally, a recent study showed 
no benefit, including lower mortality, among 
older persons who were treated for subclinical 
hypothyroidism.1 We therefore cannot agree that 
the risk of death among mothers justifies routine 
screening or treatment for subclinical thyroid 
disease during pregnancy. Nevertheless, we agree 
with Hegedüs and Brix regarding their admoni-
tion against overtreatment with levothyroxine, 
especially during pregnancy.
Haddow and Palomaki point to the results of 
their 1999 study, which focused on pregnant 
women with overt hypothyroidism and their 
offspring.2 Treatment of such women during 
pregnancy is well established and may improve 
neurocognitive outcomes in offspring, as implied 
by their original findings. Conversely, there is 
now convincing evidence that the treatment of 
subclinical hypothyroidism or hypothyroxinemia 
during pregnancy does not improve neurocogni-
tive outcomes in offspring. As Haddow and 
Palomaki suggest, the question of routine thy-
roid screening during pregnancy now seems to 
hinge on the potential benefits of detecting the 
less prevalent diagnosis of overt hypothyroidism. 
Our trial was not designed to answer this ques-
tion. However, given that overt hypothyroidism 
is relatively infrequent during pregnancy, that the 
diagnosis is frequently not confirmed on repeat 
testing during pregnancy,3 and that treatment of 
subclinical thyroid hypofunction as early as the 
second trimester has not been shown to have a 
benefit with regard to IQ in offspring, we do not 
consider universal screening for asymptomatic 
overt hypothyroidism during pregnancy to be 
justified. Since an acceptable study of sufficient 
size to answer the dilemma posed is unlikely to 
be feasible, we believe that targeted screening 
during pregnancy remains the best option.
Brian M. Casey, M.D.
University of Texas Southwestern Medical 
Dallas, TX 
brian . casey@ utsouthwestern . edu
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Washington, DC
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